跳至主要内容
临床试验/JPRN-UMIN000025085
JPRN-UMIN000025085招募中未知

Efficacy and safety of ombitasvir/paritaprevir/ritonavir, ledipasvir/sofosbuvir, elbasvir /grazoprevir, glecaprevir/pibrentasvir after curative treatment of HCV-Related HCC - Prospective multicenter-cooperative cohort study - Ombitasvir/paritaprevir/ritonavir, ledipasvir/sofosbuvir, elbasvir/grazoprevir, glecaprevir/pibrentasvir therapy in HCV-Related HCC patients - Prospective multicenter-cooperative cohort study

Juntendo University Hospital0 个研究点目标入组 80 人开始时间: 2016年12月1日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 90years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Patients who have a history of hypersensitivity to Omvitasvir/paritaprevir/ritonavir 2)Patients who are excluded from HCV eradication therapy because of decompensated cirrhosis and others 3)Patients who cannot receive IFN-free therapy because of concomitant medication etc. 4)Women who are or may be pregnant 5)Patients considered to be ineligible for participation in the study by the investigator or subinvestigators

研究者

相似试验